REFERENCES

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.

2. Righi FA, Vander Heide RS, Graham RP, et al. A case-control autopsy series of liver pathology associated with novel coronavirus disease (COVID-19). Ann Diagn Pathol. 2024;68:152240.

3. Sarin SK, Choudhury A, Lau GK, et al.; APASL COVID Task Force. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14:690-700.

4. Sonzogni A, Previtali G, Seghezzi M, Alessio MG, Gianatti A, Licini L. Liver histopathology in severe COVID-19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40:2110-6.

5. Chornenkyy Y, Mejia-Bautista M, Bruca M, Blanke T, Dittmann D, Yeldandi A. Liver pathology and SARS-CoV-2 detection in formalin-fixed tissue of patients with COVID-19. Am J Clin Pathol. 2021;155:802-14.

6. Farrokhpour M, Rezaie N, Moradi N, et al. Infliximab and intravenous gammaglobulin in hospitalized severe COVID-19 Patients in intensive care unit. Arch Iran Med. 2021;24:139-43.

7. Sekhawat V, Green A, Mahadeva U. COVID-19 autopsies: conclusions from international studies. Diagn Histopathol. 2021;27:103-7.

8. Ministerio de Salud Pública de Cuba. Anuario Estadístico de Salud. Available from: https://temas.sld.cu/estadisticassalud/publicaciones-2/anuario-estadistico-de-salud/ [accessed 27 October 2025].

9. Mejías Sánchez Y, Morales Suárez I, Arteaga García A, Alfonso Sánchez I. Estructuración del Protocolo Cubano de Actuación para la Atención de Casos COVID-19. Rev Cub Salud Publica. 2021;47(3). Available from: https://revsaludpublica.sld.cu/index.php/spu/article/view/2922 [accessed 27 October 2025].

10. Bruguera M. El examen metódico de la biopsia hepática. In: Bosch J, Rodés J, editors. Enfermedades del hígado. 3rd ed. Barcelona: Elsevier; 2006. p. 1-15. Available from: https://www.elsevier.es/libros/enfermedades-del-higado/9788445815770.

11. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8:48.

12. Barreto IDJ, Múnera Contreras MN, Suárez Causado A. Relación entre el factor de crecimiento hepático y el estadio de la cirrosis. Rev Colomb Gastroenterol. 2017;32:24. (in Spanish).

13. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.

14. Barnes GD. Predicting the quality of warfarin therapy: reframing the question. Thromb Haemost. 2019;119:509-11.

15. Heinze G, Wallisch C, Dunkler D. Variable selection - a review and recommendations for the practicing statistician. Biom J. 2018;60:431-49.

16. Yoneda M, Kobayashi T, Honda Y, et al. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. Hepatol Commun. 2022;6:2273-85.

17. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis. 2020;5:80.

18. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41:20-32.

19. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-2.

20. Liu Q, Wang RS, Qu GQ, et al. Gross examination report of a COVID-19 death autopsy. J Forensic Med. 2020;36:21-3.

21. Marjot T, Webb GJ, Barritt AS, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18:348-64.

22. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768-771.e3.

23. Moreira JLS, Barbosa SMB, Vieira JG, Chaves NCB, Gonçalves Júnior J. Liver histopathological changes and COVID-19: what does literature have to tell us? Dig Liver Dis. 2022;54:296-8.

24. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73:451-3.

25. Abenavoli L, Aquila I, Sacco MA, et al. Liver damage and impaired coagulation in COVID-19 patients: a case series. Diseases. 2023;11:141.

26. Mao R, Liang Y, Shen J, et al. Liver injury in COVID-19: mechanisms and potential therapeutic targets. Lancet Gastroenterol Hepatol. 2020;5:683-690.

27. Wang H, Qiu P, Liu J, Wang F, Zhao Q. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020;44:653-61.

28. Tazarghi A, Bazoq S, Taziki Balajelini MH, Ebrahimi M, Hosseini SM, Razavi Nikoo H. Liver injury in COVID-19: an insight into pathobiology and roles of risk factors. Virol J. 2024;21:65.

29. Cai Y, Ye LP, Song YQ, et al. Liver injury in COVID-19: detection, pathogenesis, and treatment. World J Gastroenterol. 2021;27:3022-36.

30. Shi Y, Wang M, Wu L, Li X, Liao Z. COVID-19 associated liver injury: An updated review on the mechanisms and management of risk groups. Liver Res. 2023;7:207-15.